Li Wei, Gao Wenkang, Yan Shengqi, Yang Ling, Zhu Qingjing, Chu Huikuan
Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Hubei Clinical Research Center for Infectious Diseases, Wuhan Research Center for Communicable Disease Diagnosis and Treatment, Chinese Academy of Medical Sciences, Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology and Wuhan Jinyintan Hospital, Chinese Academy of Sciences, Wuhan 430023, China.
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Biomedicines. 2024 Dec 31;13(1):74. doi: 10.3390/biomedicines13010074.
The global incidence and mortality rates of alcohol-related liver disease are on the rise, reflecting a growing health concern worldwide. Alcohol-related liver disease develops due to a complex interplay of multiple reasons, including oxidative stress generated during the metabolism of ethanol, immune response activated by immunogenic substances, and subsequent inflammatory processes. Recent research highlights the gut microbiota's significant role in the progression of alcohol-related liver disease. In patients with alcohol-related liver disease, the relative abundance of pathogenic bacteria, including , increases and is positively correlated with the level of severity exhibited by alcohol-related liver disease. Supplement probiotics like , as well as , have been found to alleviate alcohol-related liver disease. The gut microbiota is speculated to trigger specific signaling pathways, influence metabolite profiles, and modulate immune responses in the gut and liver. This research aimed to investigate the role of gut microorganisms in the onset and advancement of alcohol-related liver disease, as well as to uncover the underlying mechanisms by which the gut microbiota may contribute to its development. This review outlines current treatments for reversing gut dysbiosis, including probiotics, fecal microbiota transplantation, and targeted phage therapy. Particularly, targeted therapy will be a vital aspect of future alcohol-related liver disease treatment. It is to be hoped that this article will prove beneficial for the treatment of alcohol-related liver disease.
酒精性肝病的全球发病率和死亡率呈上升趋势,这反映出全球范围内日益严重的健康问题。酒精性肝病是由多种原因的复杂相互作用导致的,包括乙醇代谢过程中产生的氧化应激、免疫原性物质激活的免疫反应以及随后的炎症过程。最近的研究强调了肠道微生物群在酒精性肝病进展中的重要作用。在酒精性肝病患者中,包括 在内的致病细菌相对丰度增加,且与酒精性肝病所表现出的严重程度呈正相关。已发现补充益生菌如 以及 可缓解酒精性肝病。据推测,肠道微生物群会触发特定的信号通路,影响代谢物谱,并调节肠道和肝脏中的免疫反应。本研究旨在探讨肠道微生物在酒精性肝病发病和进展中的作用,以及揭示肠道微生物群可能导致其发展的潜在机制。这篇综述概述了目前用于逆转肠道微生物失调的治疗方法,包括益生菌、粪便微生物群移植和靶向噬菌体疗法。特别是,靶向治疗将是未来酒精性肝病治疗的一个重要方面。希望本文对酒精性肝病的治疗有所帮助。